IMDX — Insight Molecular Diagnostics Inc.

Summary of Insight Molecular Diagnostics (IMDX) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Low levels of revenue expected in lab services for 2026, with almost no revenue anticipated in Q1 2026.
• Cash Burn: Increased cash burn expected in the first half of 2026, averaging about $7.5 million per quarter, with a drop anticipated in the second half.
• Funding: Completed a $26 million offering to support product development and commercialization efforts.
• Reimbursement: Medicare reimbursement for GraftAssure set at $27.53, with a total addressable market valued at over $2 billion annually.

2. Strategic Updates and Business Highlights

• FDA Submission: Submitted GraftAssureDx for FDA review, marking a significant milestone as the first dd-cfDNA assay submitted for authorization.
• Registry Engagement: 28 transplant centers engaged in the GALACTIC registry, with a goal of reaching 50 centers to drive adoption and gather data.
• Head-to-Head Data: Positive preliminary results presented at a transplant meeting, showing GraftAssure's equivalence to national reference labs, leading to increased interest from transplant centers.
• Expansion Plans: Plans to expand GraftAssure into heart transplant testing, leveraging existing technology designed to be organ-agnostic.

3. Forward Guidance and Outlook

• 2026 Goals: Focus on expanding market access, driving clinical readouts, and transitioning GraftAssure to in-house testing at engaged centers.
• Market Shift: Anticipation of a shift in the organ transplant rejection testing market towards earlier detection and management of organ rejection, positioning GraftAssure favorably for future growth.
• Sales Pipeline: Engaged with 37 transplant centers, expecting an average of $1 million in annual revenue per center.

4. Bad News, Challenges, or Points of Concern

• Revenue Projections: Low expected revenue in the first quarter and overall uncertainty regarding lab services revenue for 2026.
• Cash Management: Increased cash burn and the need for careful management of expenditures, particularly in R&D and marketing.
• Regulatory Risks: The timeline for FDA approval and subsequent commercialization remains uncertain, with potential delays impacting revenue generation.
• Competition: Need to convince clinicians to adopt GraftAssure over existing methods, which may pose challenges in changing established practices.

5. Notable Q&A Insights

• Registry Participation: Participation in the registry is expected to be self-funding, with a focus on converting registry participants to in-house testing for profitability.
• Bio-Rad Agreement: A 90-day right of first negotiation for commercial rights post-FDA authorization is in place, with ongoing discussions already occurring.
• Heart vs. Liver Testing: Heart transplant testing prioritized due to higher demand and urgency in patient management compared to liver transplants.
• Billing and Coding: A Z code will be submitted for the regulated version of GraftAssure, facilitating reimbursement processes for participating hospitals.

Overall, IMDX is positioned for growth with the upcoming FDA approval and strategic expansion plans, but faces challenges related to revenue generation and market adoption.